This phase I trial tests the safety, side effects, and best dose of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pan…

Metastatic Pancreatic Neuroendocrine TumorPancreatic NeoplasmStage III Pancreatic Neuroendocrine Tumor AJCC v8+2 more

~Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05687123

Phase 1

A Phase I Study of Fulvestrant in Combination With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.

Metastatic Pancreatic Neuroendocrine Tumor

~Estimated

~$10 – $6,250

University of ChicagoNCT06663072